<?xml version="1.0" encoding="UTF-8"?>
<p>As data were completely satisfactory, Vaxart Inc. studied a combined preparation, in which an oral NoV GI.1 vaccine tablet is associated with an oral NoV GII.4 vaccine tablet that are administered concurrently. The bivalent NoV phase 1b trial includes two stages, an open-label lead-in phase that was completed successfully earlier this month, and a randomized, double-blind, placebo-controlled phase that has recently started. Both portions of the trial are designed to evaluate safety and immunogenicity, and the results are expected in a short time (
 <xref rid="B60" ref-type="bibr">60</xref>).
</p>
